Solanezumab

Summary

Solanezumab (CHEMBL1743072) is a phase-3 clinical-stage antibody; indicated across 2 conditions including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743072
Name	Solanezumab
Type	Antibody
Max phase	3

Also known as: LY-2062430, LY2062430, Solanezumab, SOLANEZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	6
PHASE2	3
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01760005	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT00904683	PHASE3	COMPLETED	Effect of LY2062430 on the Progression of Alzheimer’s Disease
NCT00905372	PHASE3	COMPLETED	Effect of LY2062430 on the Progression of Alzheimer’s Disease
NCT01127633	PHASE3	TERMINATED	Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer’s Disease
NCT01900665	PHASE3	TERMINATED	Progress of Mild Alzheimer’s Disease in Participants on Solanezumab Versus Placebo
NCT02008357	PHASE3	COMPLETED	Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
NCT02760602	PHASE3	TERMINATED	A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer’s Disease
NCT04623242	PHASE2/PHASE3	COMPLETED	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation.
NCT00329082	PHASE2	COMPLETED	Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer’s Disease and in Healthy Volunteers
NCT00749216	PHASE2	COMPLETED	Solanezumab Safety Study in Japanese Patients With Alzheimer’s Disease
NCT01148498	PHASE2	COMPLETED	A Biomarker Study of Solanezumab in Patients With and Without Alzheimer’s
NCT02614131	PHASE1	TERMINATED	A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer’s Disease (AD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).